Effect of SVF Derived MSC in DCD Renal Transplantation
Status:
Unknown status
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to determine if autologous Stromal Vascular Fraction (SVF)
derived Mesenchymal Stem Cell (MSC) infusion during and after kidney transplantation from
Donation after Citizen Death (DCD) can effectively reduce the need for post transplant
immunosuppressant and elevate GFR of allograft. The investigators will infuse autologous SVF
derived MSC to the recipients during and after operation to assess the effect of SVF derived
MSC and closely monitor renal function, dosage of immunosuppressant, acute rejection, and
graft survival. 120 patients eligible for the study as described below will be enrolled, with
60 patients in intervention group and 60 in control group.